Background illustration for clinical trials search

Paid Clinical Trials New Haven

Discover 1,147 paid clinical trials in New Haven, Connecticut. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.

Filter
2

Revumenib in Combination With 7+3 + Midostaurin in AML

for
Acute Myeloid Leukemia, AML, Adult, AML With Gene Mutations,
Location: New Haven CT, Boston MA
Sponsor: Richard Stone, MD

Sex: All

Age: 18 - 70+

Code: NCT06313437

Phase1, Recruiting

A Study of AK117 in Combination With Azacitidine in Patients With Myelodysplastic Syndromes

for
Higher-risk Myelodysplastic Syndromes
Location: New Haven CT, Bronx NY, Columbia MD, Bethesda MD,
Sponsor: Akeso

Sex: All

Age: 18+

Code: NCT06196203

Phase2, Recruiting

Open-label Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer

for
Non-small Cell Lung Cancer,
Location: New Haven CT, Norwalk CT, New York NY, Baltimore MD,
Sponsor: TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)

Sex: All

Age: 18+

Code: NCT06343402

Phase1, Recruiting

Randomized Phase IIB Trial of Oral Azacytidine Plus Romidepsin Versus Investigator's Choice in PTCL

for
PTCL
Location: New Haven CT, New York NY, Charlottesville VA,
Sponsor: University of Virginia

Sex: All

Age: 18+

Code: NCT04747236

Phase2, Recruiting

Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067

for
Cancer, Solid Tumor, Melanoma, Renal Cell Carcinoma,
Location: New Haven CT, Boston MA, Buffalo NY, Denver CO,
Sponsor: Simcha IL-18, Inc.

Sex: All

Age: 18+

Code: NCT04787042

Phase1, Phase2, Recruiting

Interested in new trials?

Get alerts for new trials in your area by subscribing now

Subscriber Image

BI-1910 as a Single Agent and in Combination With Pembrolizumab for the Treatment of Advanced Solid Tumors

for
Solid Tumors, Non Small Cell Lung Cancer,
Location: New Haven CT
Sponsor: BioInvent International AB

Sex: All

Age: 18+

Code: NCT06205706

Phase1, Phase2, Recruiting

A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence

for
Breast Cancer
Location: New Haven CT, Stony Brook NY, Westbury NY, Mineola NY,
Sponsor: Stemline Therapeutics, Inc.

Sex: All

Age: 18+

Code: NCT06492616

Phase3, Recruiting

A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies

for
Advanced or Metastatic Solid Tumors, Breast Cancer,
Location: New Haven CT, New York NY, Boston MA, Philadelphia PA,
Sponsor: 858 Therapeutics, Inc.

Sex: All

Age: 18+

Code: NCT06395519

Phase1, Phase2, Recruiting

Phase 1 Study Evaluating BA3182 in Patients With Advanced Adenocarcinoma.

for
Advanced Adenocarcinoma
Location: New Haven CT, Cleveland OH, Detroit MI, Cincinnati OH,
Sponsor: BioAtla, Inc.

Sex: All

Age: 18+

Code: NCT05808634

Phase1, Recruiting

I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer

for
Breast Neoplasms, Breast Cancer, Breast Tumors, Angiosarcoma,
Location: New Haven CT, The Bronx NY, New York NY,
Sponsor: QuantumLeap Healthcare Collaborative

Sex: All

Age: 18+

Code: NCT01042379

Phase2, Recruiting

A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)

for
Melanoma
Location: New Haven CT, Paramus NJ, Hackensack NJ, Providence RI,
Sponsor: Regeneron Pharmaceuticals

Sex: All

Age: 18+

Code: NCT06246916

Phase3, Recruiting

A Study of ASP1002 in Adults for Treatment of Solid Tumors

for
Advanced Solid Tumors
Location: New Haven CT, Plainville CT, New York NY, Fairfax VA,
Sponsor: Astellas Pharma Global Development, Inc.

Sex: All

Age: 18+

Code: NCT05719558

Phase1, Recruiting

A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)

for
Mantle Cell Lymphoma, B Cell Lymphoma
Location: New Haven CT, Paramus NJ, New York NY, Boston MA,
Sponsor: BeOne Medicines

Sex: All

Age: 18+

Code: NCT06742996

Phase3, Recruiting

Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)

for
Triple-Negative Breast Cancer
Location: New Haven CT, Farmington CT, Westbury NY, New York NY,
Sponsor: Merck Sharp & Dohme LLC

Sex: All

Age: 18+

Code: NCT06393374

Phase3, Recruiting

SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma

for
Melanoma, Cutaneous Malignant
Location: New Haven CT, New York NY, Morristown NJ, Boston MA,
Sponsor: Immatics US, Inc.

Sex: All

Age: 18+

Code: NCT06743126

Phase3, Recruiting

A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid Tumors

for
Advanced Solid Tumor, Solid Tumor
Location: New Haven CT, New York NY, Hackensack NJ, Ann Arbor MI,
Sponsor: BeOne Medicines

Sex: All

Age: 18+

Code: NCT05981703

Phase1, Recruiting

The SUGAR Study; SBRT and Relugolix) for Prostate Cancer

for
Prostate Cancer
Location: New Haven CT, New York NY, Lebanon NH, Seattle WA
Sponsor: Yale University

Sex: Male

Age: 18+

Code: NCT06111781

Phase2, Recruiting

A Study of ZL-1310 in Subjects With Small Cell Lung Cancer

for
SCLC
Location: New Haven CT, Hackensack NJ, Fairfax VA, Buffalo NY,
Sponsor: Zai Lab (Shanghai) Co., Ltd.

Sex: All

Age: 18+

Code: NCT06179069

Phase1, Recruiting

First in Human Study of TUB-030 in Patients With Advanced Solid Tumors

for
Advanced Solid Tumors, HNSCC, SCLC, NSCLC,
Location: New Haven CT, New York NY, Boston MA, Toronto,
Sponsor: Tubulis GmbH

Sex: All

Age: 18+

Code: NCT06657222

Phase1, Phase2, Recruiting

A First-in-human Study of PRTH-101 Monotherapy +/- Pembrolizumab in Subjects With Advanced Malignancies

for
Advanced or Metastatic Solid Tumors, Non Small Cell Lung Cancer,
Location: New Haven CT, Boston MA, Fairfax VA, Nashville TN,
Sponsor: Incendia Therapeutics

Sex: All

Age: 18+

Code: NCT05753722

Phase1, Recruiting